Evert Kroon

Evert Kroon

Auto-generated profile, based on publicly available information

Evert Kroon

ViaCyte Inc., San Diego, USA

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2006 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
KDKevin A D'AMour
Kevin A D'AMour
ABAnne G Bang
Anne G Bang
SESusan Eliazer
Susan Eliazer
OKOlivia G Kelly
Olivia G Kelly
AAAlan D Agulnick
Alan D Agulnick
EBEmmanuel E Baetge
Emmanuel E Baetge

20 February 2008 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
EKEvert Kroon
Evert Kroon
LMLaura A Martinson
Laura A Martinson
KKKuniko Kadoya
Kuniko Kadoya
ABAnne G Bang
Anne G Bang
OKOlivia G Kelly
Olivia G Kelly
EBEmmanuel E Baetge
Emmanuel E Baetge

28 October 2005 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
KDKevin A D'Amour
Kevin A D'Amour
AAAlan D Agulnick
Alan D Agulnick
SESusan Eliazer
Susan Eliazer
OKOlivia G Kelly
Olivia G Kelly
EKEvert Kroon
Evert Kroon
EBEmmanuel E Baetge
Emmanuel E Baetge

1 July 1998 in The EMBO Journal
Verified
Journal Article
Closed access
PDF file
EKEvert Kroon
Evert Kroon
JKJana Krosl
Jana Krosl
UTUnnur Thorsteinsdottir
Unnur Thorsteinsdottir
SBSoheyl Baban
Soheyl Baban
ABArthur M. Buchberg
Arthur M. Buchberg
GSGuy Sauvageau
Guy Sauvageau

18 May 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TSThomas C. Schulz
Thomas C. Schulz
HYHolly Y. Young
Holly Y. Young
AAAlan D. Agulnick
Alan D. Agulnick
MBM. Josephine Babin
M. Josephine Babin
EBEmmanuel E. Baetge
Emmanuel E. Baetge
ARAllan J. Robins
Allan J. Robins
Development of a human embryonic stem cell (hESC)-based therapy for type 1 diabetes will require the translation of proof-of-principle concepts into a scalable, controlled, and regulated cell manufacturing process. We have previously demonstrated that hESC can be directed to differentiate into pancreatic progenitors that mature into functional glucose-responsive, insulin-secreting cells in vivo. In this study we describe hESC expansion and banking methods and a suspension-based differentiation system, which together underpin an integrated scalable manufacturing process for producing pancreatic progenitors. This system has been optimized for the CyT49 cell line. Accordingly, qualified large-scale single-cell master and working cGMP cell banks of CyT49 have been generated to provide a virtually unlimited starting resource for manufacturing. Upon thaw from these banks, we expanded CyT49 for two weeks in an adherent culture format that achieves 50–100 fold expansion per week. Undifferentiated CyT49 were then aggregated into clusters in dynamic rotational suspension culture, followed by differentiation en masse for two weeks with a four-stage protocol. Numerous scaled differentiation runs generated reproducible and defined population compositions highly enriched for pancreatic cell lineages, as shown by examining mRNA expression at each stage of differentiation and flow cytometry of the final population. Islet-like tissue containing glucose-responsive, insulin-secreting cells was generated upon implantation into mice. By four- to five-months post-engraftment, mature neo-pancreatic tissue was sufficient to protect against streptozotocin (STZ)-induced hyperglycemia. In summary, we have developed a tractable manufacturing process for the generation of functional pancreatic progenitors from hESC on a scale amenable to clinical entry.

1 August 2011 in Nature Biotechnology
Verified
Journal Article
Closed access
OKOlivia G Kelly
Olivia G Kelly
MCMan Yin Chan
Man Yin Chan
LMLaura A Martinson
Laura A Martinson
KKKuniko Kadoya
Kuniko Kadoya
TOTraci M Ostertag
Traci M Ostertag
ABAnne G Bang
Anne G Bang